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The α-Thalassemia/mental retardation X-linked 
(ATRX) chromatin remodeler is a component of 
constitutive heterochromatin [1-5] and is exclusively 
nuclear [4]. The C-terminus of ATRX contains a 
Switch/Sucrose non-fermenting (Swi/Snf) domain [6] 
which confers the ATPase and translocase activity of 
ATRX necessary for nucleosome remodelling [7].  The 
N-terminus of ATRX contains an ADD domain 
(ATRX-DNTM3-DNTM3L) with homology to the  DNA 
 
 
methyltransferase family and is capable of binding 
methylated histone tails within chromatin [8].  
 
ATRX is essential for heterochromatin [5, 9] and 
telomere integrity [9, 10], as well as normal gene 
expression [11-15]. Deletion of ATRX in neuro-
progenitor cells (NPCs) causes DNA damage at 
telomeres and pericentromeric heterochromatin [10]. 
We have previously shown that telomestatin-mediated 
stabilization of G-quadruplexes exacerbated DNA 
damage and decreased viability of NPCs in the absence 
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ATRX  is  an  ATP‐dependent  chromatin  remodeler  required  for  the  maintenance  of  genomic  integrity.  We




stimulates expression of  IGF‐1  in pre‐pubertal mice, we  tested whether T4 supplementation  in Atrx Foxg1cre
mice could restore IGF‐1 levels and ameliorate premature aging‐like phenotypes. Despite restoration of normal
serum T4  levels, we did not observe  improvements  in  circulating  IGF‐1.  In  the  liver,  thyroid hormone  target
genes were differentially affected upon T4 treatment, with Igf1 and several other thyroid hormone responsive
genes failing to recover normal expression levels. These findings hinted at Cre‐mediated Atrx inactivation in the
liver  of  Atrx  Foxg1cre  mice,  which  we  confirmed.  We  conclude  that  the  phenotypes  observed  in  the  Atrx
Foxg1cre mice can be explained in part by a role of ATRX in the liver to promote T4‐mediated Igf1 expression,
thus explaining the inefficacy of T4 therapy observed in this study. 
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of ATRX [10]. ATRX may be facilitating the 
progression of DNA replication and transcriptional 
machinery through these non-canonical DNA structures 
[10, 12]. 
 
We previously reported that postnatal health and 
longevity are severely affected in mice with forebrain 
and anterior pituitary-specific deficiency for ATRX 
(Atrx Foxg1cre) [10].  Many of the abnormalities 
detected in these mice resemble those previously 
reported in mouse models of progeria, including low 
circulating levels of IGF-1 [16-20].  Progeroid synd-
romes are a group of disorders characterized by 
accelerated physiological aging. These heritable 
disorders produce signs of premature aging in many, but 
not all tissues and therefore are termed segmental 
progerias. It has been postulated that in progeroid 
syndromes, mutations in genome repair genes result in 
increased genomic and heterochromatin instability [21, 
22].  This is paired with the downregulation of genes 
involved in growth, such as Igf1, presumably in order to 
survive the damage [23]. However, if this occurs during 
development, it is detrimental to the organism, resulting 
in metabolic defects and premature aging. Several 
progeroid syndromes have been described, such as 
Cockayne syndrome [24], Werner syndrome [25] and 
Hutchinson-Gilford progeria [26].  Symptoms of these 
disorders typically include reduced growth, decreased 
lifespan, bone and organ abnormalities and loss of 
subcutaneous fat. 
 
The role of insulin signalling in aging and longevity is 
highly conserved [27]. IGF-1 is predominantly 
produced by the liver and important for stem cell 
proliferation in many organs and some evidence points 
to depleted stem cell pools as a main cause of aging [28, 
29]. A case in point is Hutchinson-Gilford progeria, 
which is caused by mutations in Zmpste24, a metallo-
peptidase involved in the processing of lamin A [19]. 
When lamin A is mutated, the nuclear membrane is 
unable to form properly, resulting in DNA damage and 
genome instability [19]. Zmpste24 null mice exhibit 
accelerated aging phenotypes and low levels of 
circulating IGF-1 [19].  Remarkably, treatment of these 
mice with IGF-1 results in amelioration of aging 
features and extends lifespan, demonstrating that 
reduction of IGF-1 levels is a cause rather than an effect 
of premature aging [19]. 
 
Xing et al. (2012) showed that mice deficient in thyroid 
hormone also exhibit premature aging phenotypes 
associated with greater than 50% decrease in Igf1 
expression in liver and bone [30]. In this case, treatment 
with both the prohormone thyroxine (T4) and the active 
hormone triiodothyronine (T3) rescued IGF-1 levels as 
well as the phenotypic defects [30]. Thyroid hormone 
mediated gene expression is regulated through the 
binding of T3 to the thyroid hormone receptors (Thrs). 
Thrs act as transcription factors to either enhance or 
repress transcription depending on whether T3 is bound 
or not [31, 32]. Moreover, Visser et al. (2016) reported 
suppressed thyroid hormone signaling and increased 
expression of the thyroid hormone deactivating enzyme 
deiodinase 3 (Dio 3) in mouse models of Xeroderma 
pigmentosa, Cockayne syndrome and in wild type aged 
mice [33]. Taken together, this evidence suggests that 
thyroid hormone signalling is implicated in progeria 
through the regulation of IGF-1 in early postnatal 
development.  
 
Given that the Atrx Foxg1cre mice exhibit signs of 
accelerated aging as well as reduced levels of T4 and 
IGF-1, we hypothesized that T4 treatment could rescue 
abnormalities in these mice and perhaps extend 
longevity.  Our findings demonstrate that, contrary to 
our expectation, T4 administration does not rescue IGF-
1 serum levels nor the associated adverse phenotypes. 
Upon further investigation, we found that Atrx is partially 
deleted in the liver of Atrx Foxg1Cre mice and is required 
for the expression of a subset of thyroid hormone 
responsive genes, including Igf1, providing a potential 




T4 administration does not improve body growth of 
Atrx Foxg1cre mice 
 
We previously reported that Atrx Foxg1cre mice have 
reduced weight, length and a very short lifespan 
associated with low T4 and IGF-1 [10].  To test whether 
T4 injections in the postnatal period might ameliorate 
deleterious outcomes in these mice, we established a 
protocol consisting of daily injections of three different 
doses of L-thyroxine (T4) or PBS as a control, based on 
Xing et al. 2012 [30]. Cohorts of Atrx Foxg1cre 
(indicated as cKO in figures) and control mice (in-
dicated as Ctrl in figures) were injected sub-cutaneously 
with 0.1, 0.5 or 1.0 mg/kg T4 daily from birth to P14. 
Atrx Foxg1cre mice injected with T4 did not show 
lifespan extension at any dose of T4 (Figure 1A). 
Furthermore, injection protocols with 0.5 and 1.0 mg/kg 
resulted in decreased average lifespan compared to Atrx 
Foxg1cre mice + PBS (Figure 1A and Supplementary 
Figure 1). We thus used the lowest dose of T4 (0.01 
mg/kg) for subsequent analyses. We confirmed that at 
this lower dose, T4 levels were restored to control levels 
and were significantly increased compared to sham-
treated Atrx Foxg1cre mice (Figure 1B). If T4 levels in 
Atrx Foxg1cre mice differed from the control mean by 
more than 2 standard deviations, they were considered 
biological outliers and removed from the study 
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(Supplementary Figure 2A). In order to determine 
whether serum T3 (the active form of thyroid hormone) 
was increased after T4 treatment in Atrx Foxg1cre mice, 
a T3 ELISA was performed (Supplementary Figure 2B). 
However, due to the low levels of T3 in the serum (1 
ng/mL) we were unable to detect a change in any of the 
groups at this low level.  
 
As previously reported, we observed that the weight of 
PBS-injected Atrx Foxg1cre mice was significantly 
lower than PBS-injected control mice over time and this 
effect was not rescued following T4 treatment (Figure 
1C). Weight and length measurements at P14 show that 
both PBS- or T4-injected Atrx Foxg1cre mice weigh 
less than half of controls and are shorter in length 
(Figure 1D). These results indicate that, contrary to our 
expectation, restoration of normal circulating T4 levels 
in Atrx Foxg1cre mice failed to improve their reduced 





































Low subcutaneous fat and blood glucose are not 
improved by T4 administration 
 
The Atrx Foxg1cre mice were previously reported to 
have very low levels of subcutaneous fat and serum 
glucose [10]. To measure the effects of T4 injections on 
these parameters, we examined skin sections and blood 
taken from P20 Atrx Foxg1cre mice treated with PBS or 
T4. These analyses confirmed our previous findings that 
subcutaneous fat thickness was significantly reduced in 
Atrx Foxg1cre mice compared to controls; however, it 
was not improved in T4-treated Atrx Foxg1cre mice and 
appears to be further reduced (Figure 2A).  In contrast, 
thickness of the dermal layer was not affected by the 
deletion of Atrx or T4 treatment.  A similar outcome 
was observed with serum glucose level, which was 
significantly decreased in both PBS- and T4-treated 
Atrx Foxg1cre mice compared to control mice (Figure 










































www.aging‐us.com  1226  AGING 
Atrx Foxg1cre mice were decreased in size when 
compared to control. Upon T4 treatment, we observed a 
slight increase in liver and spleen weights (relative to 
body weight) in Atrx Foxg1cre mice, but it was not 
significantly different from either PBS treated or control 
mice (Supplementary Figure 3). At P20, heart weight 
was unchanged in Atrx Foxg1cre treated with PBS 
compared to control, however following treatment with 
T4, heart weight increased significantly (Supplementary 
Figure 3). In summary, subcutaneous fat and serum 
glucose levels were not rescued by T4 treatment in Atrx 
Foxg1cre mice. 
 
T4 administration fails to recover circulating and 
hepatic IGF-1 levels 
 
We confirmed that Atrx Foxg1cre serum IGF-1 level at 
P14 is 17.7% that of control mice (Figure 3A). 
However, recovery of normal T4 circulating levels did 
not result in the expected increase of serum IGF-1. 
Given that the liver is the major source of circulating 
IGF-1, we next examined liver Igf1 expression by 
quantitative reverse transcriptase PCR (RT-qPCR) and 
found that Igf1 expression is significantly decreased in 
the liver of Atrx Foxg1cre mice, even after T4 






























The decrease in serum IGF-1 in Atrx Foxg1cre mice 
could be due to alterations in Igf1 receptor (Igf1r) or 
Igf2 receptor (Igf2r) expression.  IGF-1 binds Igf1r, 
which elicits an intracellular response, whereas Igf2r 
acts as a scavenger receptor and no response occurs. 
While Igf1r expression is not altered in the liver, Igf2r 
expression is decreased in the Atrx Foxg1cre compared 
to control as previously reported [10] and not recovered 
by T4 treatment (Figure 3B). These data provide 
evidence that IGF-1 is able to bind Igf1r and is not 
subject to deactivation by high levels of Igf2r. 
 
Serum IGF-1 could also be decreased due to gene 
expression alterations in IGF binding proteins (IGFBPs) 
and acid labile subunit (IGFALS). Both IGFALS and 
IGFBPs bind IGF-1, enhancing or diminishing IGF-1 
signaling depending on the need of the cell. Igfals and 
Igfbps are aberrantly expressed in livers of Atrx 
Foxg1cre mice compared to controls. Igfals expression 
is significantly decreased in Atrx Foxg1cre mice + PBS 
compared to control and is not rescued by T4 treatment. 
Igfbp1 and Igfbp2 expression are significantly increased 
in Atrx Foxg1cre compared to control mice.  Igfbp2, but 
not Igfbp1 expression is restored to control levels in 
Atrx Foxg1cre + T4. Low Igfbp2 expression has been 
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sion is likely due to a feedback mechanism following 
increased serum T4. Igfbp3 expression is decreased in 
the Atrx Foxg1cre + PBS and not restored to control 
levels following T4 treatment (Figure 3C) These results 
indicate that despite restoring serum T4 levels, most 
genes involved in IGF-1 signalling are still aberrantly 
expressed.  
 
T4 administration restores thyroxine binding 
globulin gene expression and a subset of thyroid 
hormone responsive genes in the liver of Atrx 
Foxg1cre mice 
 
Alterations in the gene Serpina7 (thyroxine binding 
globulin (TBG)), one of the thyroid hormone transport 
molecules, could also affect transport of T4. Serpina7 is 
significantly increased in the Atrx Foxg1cre + PBS and 
is restored to control levels following treatment with T4 
(Figure 4A). We next examined the effect of T4 
injections on the expression of several thyroid hormone 
target genes in the liver of Atrx Foxg1cre mice. Dio1, 
which converts T4 to its active form T3, is expressed at 
slightly decreased levels in Atrx Foxg1cre liver, 
































verts T3 to the inactive forms rT3 and T2, is normally 
expressed embryonically when precise control over 
thyroid hormone signalling is crucial. Dio3 was 
reported to be reactivated in the liver of two mouse 
models of premature aging and in normal mouse aging 
[33]. Dio3 is slightly increased in Atrx Foxg1cre mice 
compared to control, however not significantly (Figure 
4B). Following T4 treatment Dio3 expression is highly 
repressed and is significantly decreased in Atrx 
Foxg1cre mice + T4 compared to Atrx Foxg1cre mice + 
PBS, suggesting that T4 is converted to the T3 active 
form. Thyroid hormone receptor β (Thrβ), the active 
thyroid hormone receptor in the liver, is decreased in 
the Atrx Foxg1cre + PBS compared to control. When 
treated with T4, Thrβ expression is restored to control 
levels and is significantly increased compared to Atrx 
Foxg1cre + PBS (Figure 4B). 
 
Despite proper regulation and activation of thyroid 
hormone in the liver, expression of thyroid hormone 
responsive genes Prlr, Ghr and Thrsp were not restored 
to control levels in Atrx Foxg1cre mice treated with T4 
(Figure 4C). While the liver of Atrx Foxg1cre mice 
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that this is not the case and that it fails to respond to 
normal thyroid hormone signalling. This prompted us to 
investigate the possibility that Foxg1Cre expression 
might be spuriously activated in the liver of these mice, 
causing Atrx gene inactivation. 
 
Cre recombinase expression and Atrx deletion in the 
liver of Atrx Foxg1cre mice 
 
We had previously verified by western blot analysis that 
ATRX protein levels were normal in the liver in P20 
Atrx cKO mice [10]. However, given the results above, 
we re-examined the status of ATRX in the liver. To 
achieve this, we introduced the ROSAmT/mG reporter 
allele into the Atrx Foxg1cre mice to allow immuno-
fluorescent detection of Cre-recombinase activity 
through the detection of green fluorescent protein 
(GFP), while cells that have never been exposed to Cre-
recombinase activity display red fluorescent protein 
(RFP). Immunofluorescence detection of RFP and GFP 
in liver cryosections at either P14 (Figure 5A) or P20 
(Figure 5D) in Atrxwt/Y; Foxg1cre; Rosa mTmG 
(controls) and Atrxf/Y;Foxg1cre;Rosa mTmG (cKO) 
































liver. To verify that this resulted in loss of ATRX 
protein, we performed immunofluorescence staining of 
ATRX in liver cryosections at either P14 (Figure 5B) or 
P20 (Figure 5E). Quantification revealed a significant 
reduction in the proportion of cells that express ATRX 
in the liver of Atrx Foxg1cre mice compared to controls 
at both P14 (Figure 5C) and P20 (Figure 5F). These 
results indicate that Cre-mediated Atrx inactivation 
occurred in the liver of Atrx Foxg1cre mice. However, 
at P20, we noted an increase in the total number of cells 
in the Atrx Foxg1cre liver, and that many oblong-
shaped cells expressed high levels of ATRX when 
compared to control (Figure 5F). We speculate that 
these cells represent a regenerative event mediated by 
proliferating ATRX+ Kupffer or stellate cells, likely 
explaining the lack of difference in the levels of ATRX 
protein previously observed in the P20 liver of Atrx 
Foxg1cre mice by Western blot analysis [10]. Immuno-
fluorescence detection of ATRX and either albumin 
(hepatocyte marker), F4/80 (Kupffer cell marker) or 
GFAP (stellate cell marker) in Atrx Foxg1cre mice 
revealed that cells lacking ATRX co-express albumin 
but not F4/80 or GFAP, indicating that Cre-mediated 


































Figure  4.  T4  administration  restores  thyroxine  binding  globulin  gene  expression  and  a  subset  of  thyroid  hormone
responsive genes in the liver of Atrx Foxg1cre (cKO) mice at P14. (a) Serpina7 (thyroxine binding globulin) gene expression  is























































































































GFP expression  (b) ATRX  immunofluorescence of  liver  cryosections  at P14  shows  that many nuclei do not express ATRX protein.
White box outlines magnified area below. Scale bar = 50 µm. Representative  image of n=3 Ctrl/cKO pairs.  (c) Cell counts of ATRX+
cells reveal a significant reduction  in the proportion of ATRX+ cells  in Atrx Foxg1cre compared to control  liver at P14 despite equal
number of cells. (d) Immunofluorescence detection of RFP and GFP in P20 liver of Atrx Foxg1cre; ROSAmT/mG mice shows expression
of shows Cre‐mediated GFP expression.  (e) ATRX staining  in  liver cryosections at P20 shows presence of ATRX‐null nuclei and  the
accumulation of bright ATRX+ cells. White box outlines magnified area below. Scale bar = 50 µm. (Representative  images from n=3
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Increased expression of subset of thyroid hormone 
responsive genes upon T4 administration require 
ATRX expression  
 
Several thyroid hormone responsive genes (Igf1, Prlr, 
Ghr and Thrsp) failed to respond to T4 treatment in Atrx 


















































might require ATRX. To test this, we compared the 
effect of T4 treatment of control and Atrx FoxG1cre 
mice on the expression of Igf1, Prlr, Ghr and Thrsp in 
the liver. The results show that these thyroid hormone 
responsive genes are induced by T4 in control mice, but 
not in Atrx mutants (Figure 6), confirming a dependence 



















































Figure  7. ATRX  is  required  for  the  transcription  of  several
thyroid hormone responsive genes in the liver. In the control, T4
is  bound  to  thyroxine  binding  globulin  (TBG)  in  the  blood.  It  is
converted to T3  in the  liver by Dio1. Both T4 and T3 can be  inactivated
by  Dio3  to  produce  the  inactive  molecules  T2  and  rT3.  T3  binds  its
receptor Thrβ (found as a heterodimer with retinoid x receptor), which
enters  the  nucleus,  binds  a  thyroid  hormone  responsive  element  and
initiates transcription. In Atrx Foxg1cre mice there is an increase in TBG
and a decrease  in T4  in  the  serum.  In  the  liver,  there  is a decrease  in
Dio1 and an  increase  in Dio3. Any T4 present  is  likely converted to rT3.
Low  levels  of  Thrβ  acts  as  a  transcriptional  repressor.  Following
treatment with T4 in Atrx Foxg1cre mice, there are control levels of TBG
and  T4  in  the blood.  In  the  liver, Dio1  is  at  control  levels  and Dio3  is
repressed.  T4  is  converted  to  T3  where  it  binds  its  receptor  and
transcription occurs normally. This occurs  for a  subset of genes  (Dio1,
Dio3 and Thrβ). However, some genes (Igf1, Prlr, Ghr and Thrsp) are still
transcriptionally  repressed  following  T4  treatment.  This  suggests  that
ATRX  is  required  for  the  transcription  of  some  thyroid  hormone
responsive genes. 
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DISCUSSION 
 
Low serum IGF-1 has been implicated as a driver of 
premature aging syndromes [19, 30]. More recently, 
thyroid hormone signalling suppression has been linked 
to both premature aging and normal aging in mice [30, 
33]. Given the previous observation that the Atrx 
Foxg1cre mice have both low T4 and IGF1 [10], we 
tested the effects of T4 injections.  Despite recovery of 
normal T4 levels, the signalling that promotes Igf1 
expression in the liver defective, likely due to 
previously unrecognized Cre-mediated inactivation of 
the Atrx gene in the liver.  Thus, while several thyroid 
hormone target genes were responsive to T4 treatment, 
several others, including Igf1, were not, suggesting that 
ATRX is required for the induction of these genes in the 
liver. As a result, T4 administration does not rescue 
decreased lifespan, reduced growth or other defects in 
Atrx Foxg1cre mice. 
 
Higher doses of T4 that we initially tested (0.5 and 1.0 
mg/kg daily) were likely inducing hyperthyroidism in 
these small, young mice. The lowest dose, 0.1 mg/kg T4 
daily, appeared to have variable effects as some Atrx 
cKO mice injected received well above control levels or 
levels similar to uninjected Atrx FoxG1cre mice. 
Whether this was experimental error or Atrx FoxG1cre 
mice have variable absorption is unknown. Never-
theless, we used only Atrx FoxG1cre mice that 
expressed control levels of serum T4 after treatment for 
subsequent analyses. Our results suggest that restoring 
normal levels of serum T4 in Atrx FoxG1cre mice does 
not ameliorate premature aging phenotypes. It is 
known that hyperthyroidism causes increased meta-
bolic rate, reduced bone density and osteoporosis [34]. 
Due to the small size of the Atrx FoxG1cre mice 
(46.3% of control weight), it is possible that Atrx 
FoxG1cre mice received levels of T4 that are too high 
for their body weight and that a lower dose is necessary 
to eliminate induction of hyperthyroidism in this model. 
Since Igf1r appears to be unaffected by deletion of 
ATRX, a future experiment would be to directly inject 
IGF-1 in Atrx Foxg1cre mice. It has been shown in a 
Hutchinson-Gilford Progeria mouse model that IGF-1 
treatment extends lifespan and delays onset of 
premature aging [19]. 
 
The inefficacy of T4 treatment in our study could be 
explained by deletion of Atrx in the liver of Atrx 
Foxg1cre mice, which was not previously reported. 
Dio1, Serpina7 and Thrβ transcript levels were 
normalized by T4 treatment, indicating that hepatic T3 
is produced and that thyroid signalling is at least 
partially intact. Conversely, several thyroid hormone 
responsive genes including Igf1, Prlr, Ghr and Thrsp 
were not rescued following T4 treatment. Furthermore, 
when controls were treated with T4, these genes all 
increased compared to control levels. These data 
suggest that ATRX must be required for T3-mediated 
transcription of a subset of genes in the liver.   
 
It is still unknown why deletion of Atrx in the liver 
disrupts proper signalling and production of IGF-1.  
ATRX contains several LXXLL-type motifs required to 
bind hormone receptors and in the testes, it was shown 
that ATRX is able to bind the androgen receptor, 
facilitating transcription of androgen receptor target 
genes [15]. Therefore, it is possible that ATRX binds and 
cooperates with the thyroid hormone receptor directly to 
modulate gene expression in the liver. Moreover, a recent 
report strongly implicates ATRX in the regulation of 
gene expression in the liver [35].  It was shown that the 
nucleotide excision repair (NER) structure-specific 
endonuclease ERCC1–XPF, a complex that is mutated in 
premature aging, recruits the CTCF–cohesin complex, 
MBD2 and ATRX to promoters and imprinting control 
regions (ICRs) to silence a subset of imprinted genes 
during hepatic development [35].  
 
ATRX deletion has been shown to result in DNA 
replication stress and telomere abnormalities [10]. It is 
also possible that in addition to low levels of IGF-1, 
DNA damage is accumulating in hepatocytes lacking 
ATRX and these cells are dying or becoming senes-
cent, further exacerbating low levels of stem cells in the 
liver. In the future, it will be important to investigate the 
full extent of ATRX function in the liver and to further 





Mouse husbandry and genotyping 
 
Mice were exposed to 12-hour light/12-hour dark cycles 
and fed tap water and regular chow ad libitum. The 
AtrxloxP mice have been described previously [36, 37]. 
AtrxloxP mice, when mated to mice expressing Cre 
recombinase under the control of the Foxg1 promoter 
(Foxg1KiCre, RRID:MGI:3767191) [38], produce male 
progeny with Atrx deficiency in the forebrain and 
anterior pituitary (AtrxloxP;Foxg1KiCre or Atrx 
Foxg1cre for simplicity, RRID:MGI:3530074). Ear or 
tail genomic DNA was used for genotyping. Atrx, Cre, 
and Sry genotyping was performed by PCR as 




Control and Atrx Foxg1cre mice were injected 
subcutaneously from birth (P0) until P14 with 0.1, 0.5 
or 1.0 mg/kg L-thyroxine (T4) (Sigma, T2376-100MG). 
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Measurements of T4, T3, IGF-1, and glucose 
 
Plasma samples were collected from P14 mice. Blood 
was collected from the inferior vena cava. EDTA pH 
7.0 was added to the blood sample and centrifuged at 
10000 RPM for 10 minutes at 4°C. Plasma supernatant 
was collected and kept frozen at –80°C. Plasma T4 was 
assayed using a mouse T4 ELISA kit (Calbiotech, 
T4044T-100) according to the manufacturers’ instruct-
tions. Plasma T3 was assayed using a mouse T3 ELISA 
kit (T3043T-100) according to the manufacturers’ 
instructions. Plasma IGF-1 content was measured using 
a mouse IGF-1 ELISA kit (R&D Systems, MG100) 
according to the manufacturers’ instructions. Blood 
glucose levels were measured prior to sacrifice using 
the ReliOn Prime Blood Glucose Meter according to the 
manufacturer’s instructions. 
 
Hematoxylin and eosin staining of skin sections 
 
P20 mice were perfused with 4% paraformaldehyde 
before PBS washes and dehydration. Skin tissue was 
flash-frozen in liquid nitrogen using Cryomatrix 
(ThermoFisher Scientific) cryoprotectant  [39] and 
sectioned at 8µm (Leica CM 3050S). H&E staining was 
performed as follows: CAT hematoxylin (Biocare 
Medical) for 2 minutes, wash for 30 seconds, Tasha’s 
bluing solution (Biocare Medical) for 30 seconds, wash 
for 10 minutes, eosin Y (Biocare Medical) for 2 
minutes, 70% ethanol for 1 minute, 90% ethanol for 1 
min, 100% ethanol for 4 min, Xylene for 15 minutes. 
Slides were mounted with permount (Fisher Scientific). 
 
Immunofluorescence and antibodies 
 
P14 or P20 mice were perfused with 4% paraformal-
dehyde before PBS washes and dehydration. Liver 



















matrix (ThermoFisher Scientific) cryoprotectant [39] 
and sectioned and sectioned at 8µm (Leica CM 3050S). 
For immunofluorescence staining of cryo-sections, 
antigen retrieval was performed on slides by warming 
10 mM sodium citrate pH 6 solution to approximately 
95°C and microwaving slides in solution for 10 minutes 
on low. After cooling, slides were washed, blocked with 
10% normal goat serum (Sigma-Aldrich) for 1 hour and 
incubated with primary antibody overnight at 4°C. 
Slides were washed in PBS and incubated with 
secondary antibody for 1 hour. Sections were counte-
rstained with DAPI (Sigma-Aldrich) and mounted with 
permafluor (ThermoFisher Scientific). The following 
primary antibodies were used: anti-ATRX, rabbit 
polyclonal (1:75, Santa-Cruz Biotechnology, sc-15408, 
RRID:AB_2061023), anti-GFP, chicken polyclonal 
(1:150, ThermoFisher Scientific, PA1-9533, 
RRID:AB_1074893), anti-RFP, rabbit polyclonal 
(1:150, Rockland, 600-401-379, RRID:AB_2209751), 
anti-Albumin, goat polyclonal (1:600, Bethyl, A90-134, 
RRID:AB_67120), anti-F4/80, rat monoclonal (Abcam, 
ab6640, RRID:AB_ 1140040), anti-GFAP, mouse 
monoclonal (Sigma-Aldrich Cat# G3893, 
RRID:AB_477010). The secondary antibodies used 
were goat anti-rabbit-Alexa Fluor 594 (1:800 dilution; 
ThermoFisher Scientific, A-11012, 
RRID:AB_2534079), goat anti-chicken-Alexa Fluor 
488 (1:800 dilution; ThermoFisher Scientific, A-11039, 
RRID:AB_2534096), goat anti-mouse-Alexa Fluor 488 
(1:800 dilution; ThermoFisher Scientific, A-21121, 
RRID:AB_2535764) and goat anti-rat-Alexa Fluor 488 
(1:800 dilution; Thermo Fisher Scientific, A-11006, 
RRID:AB_2534074). 
 
Microscopy and imaging  
 
Hematoxalin and eosin images were captured using a 




















Gene Name Forward Primer Reverse Primer 
Igf1 ACC TCA GAC AGG CAT TGT GG GTT TGT CGA TAG GGA CGG GG 
Igf1r TGT GGT CAA GGA TGA ACC CG CCT TGG GAT ACC ACA CCC AG 
Igf2r GCA TCT TTC CAC CAG TTC CG GCT CGT CCT CAT TGT CAT CC 
Igfals CAC ACA ACG CCA TCA CTA GC CGT TGA AGA GGC CAA AGA AG 
Igfbp1 AGC CCA GAG ATG ACA GAG GA GTT GGG CTG CAG CTA ATC TC 
Igfbp2 GCG GGT ACC TGT GAA AAG AG AAC ACA GCC AGC TCC TTC AT 
Igfbp3 GTG ACC GAT TCC AAG TTC CA TGT CCT CCA TTT CTC TGC GG 
Serpina7 CCT TCC AAA AGA GGG ACA CA CCA AGG TCA TAT GTG GCA GA 
Dio1 GGA CAC AAT GCA GAA CCA GA GCA AAG CTT TTC CAG GAC AG 
Dio3 GTT TTT GGC TTG CTC TCA GG CAA CAA GTC CGA GCT GTG AA 
Thrβ CAG AAC CCA CGG ATG AGG AG GGC ATT CAC AAT GGG TGC TT 
Prlr GCA TCT TTC CAG CAG TTC CG GCT CGT CCT CAT TGT CAT CC 
Ghr ATT CAC CAA GTG TCG TTC C TCC ATT CCT GGG TCC ATT CA 
Thrsp ACG GAG CCC CTG ATC TCT AT GGC TTC TAG GTC CAG CTC CT 
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sole imaging software was used for automated image 
capture and processing was performed using Volocity 
software (PerkinElmer). Immunofluorescence images 
were captured using an inverted microscope (DMI 
6000b, Leica). Digital microscopy images were captur-
ed with a digital camera (ORCA-ER, Hamamatsu). 
Openlab imaging software was used for manual image 
capture, and processing was performed using Volocity 
software (PerkinElmer).  
 
Quantitative reverse transcriptase PCR (qRT-PCR) 
 
Total RNA was isolated from liver with the RNeasy 
Mini Kit (QIAGEN) and reverse transcribed into cDNA 
as described previously [40]. Control reactions without 
reverse transcriptase were prepared in parallel. cDNA 
was amplified with gene-specific primers under the 
following conditions: 25–35 cycles of 95°C for 30 
seconds, 60°C for 30 seconds, and 72°C for 1 minute. 
For qRT-PCR, cDNA was amplified with iQ SYBR 
Green Master Mix (Bio-Rad) by using the standard 
curve Ct method of quantification. Experiments were 
performed on a Chromo-4 thermocycler (MJ Research) 
and analyzed with Opticon Monitor 3 and GeneX 
(Bio-Rad) software. Gene expression analysis was 
repeated in duplicate for each sample. Conditions for 
amplification were as follows: 35 cycles of 95°C for 
10 seconds, 55°C for 20 seconds, 72°C for 30 seconds, 
and a final melting curve generated in increments of 





 Statistical analysis was performed using GraphPad 
Prism6 software (6.05; GraphPad Software Inc.), and all 
results are expressed as the mean ± SEM unless 
indicated otherwise. Two independent data sets were 
compared with the Student’s t test (unpaired, 2-tailed). 
Multiple independent data sets were compared with a 
one-way ANOVA with post-hoc Tukey’s test. 
Statistical analyses of Kaplan-Meier survival curves 
were performed using the log-rank test and the Gehan-
Breslow-Wilcoxon test. A repeated-measures poly-
nomial modeling analysis (SAS v.9.4, SAS Institute 
Inc., Cary, NC, USA) was used to compare differences 
between groups in weight over time. P values of 0.05 or 
less were considered to indicate significance. 
 
Study approval  
 
All procedures involving animals were conducted in 
accordance with the regulations of the Animals for 
Research Act of the Province of Ontario and approved 




IGF-1, insulin-like growth factor 1; T4, thyroxine; 
ATRX, α-Thalassemia/mental retardation X-linked; 
Swi/Snf, Switch/Sucrose non-fermenting; ADD, 
ATRX-DNTM3-DNTM3L; NPC, neuroprogenitor cell; 
T3, triiodothyronine; Thr, thyroid hormone receptor; 
Dio3, deiodinase 3; Igf1r, Igf1 receptor; Igf2r, Igf2 
receptor; IGFBP, insulin-like growth factor binding 
protein; IGFALS, insulin-like growth factor acid labile 
subunit; TBG, thyroxine binding globulin; Thrβ, 
Thyroid hormone receptor β; GFP, green fluorescent 
protein; NER, nucleotide excision repair; ICR, 
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Supplementary  Figure  1.  T4  supplementation  does  not  improve  lifespan  in
Atrx  FoxG1cre  (cKO)  mice.  Average  lifespan  was  not  significantly  changed





mice  following  T4  treatment.  Biological  outliers  are  represented  as  squares  and  these mice were
excluded  from  further  analyses.  (b) Graph  of  serum  T3  levels  in  Atrx  FoxG1cre mice  following  T4
treatment. Groups with the same  letter have means that are not significantly different. Groups with
different letters have means that are significantly different (p<0.05). Error bars represent SEM. 






























have means  that  are  not  significantly  different.  Groups with  different  letters  have means  that  are
significantly different (p<0.05). Data were normalized to body weight, n=3‐6. Error bars represent SEM.
